

## Session 1: Children

Chair: Prof  
Hermione Lyall,  
Imperial

Discussant:  
Prof Sarah Rowland-  
Jones, Oxford

Joining the dots:  
maternal HIV, CMV,  
and the placenta  
*Prof Clive Gray,  
University of Cape  
Town, South  
Africa*\*\*\*

The relationship  
between maternal  
CMV viremia during  
pregnancy and  
health outcomes in  
rural Zimbabwe  
*Dr Ceri Evans,  
University of  
Liverpool, UK*

Immune profile in  
early infant CMV  
*Prof Andrew  
Prendergast, Queen  
Mary University of  
London, UK*

Predicting the  
outcome of  
congenital and post-  
natal  
cytomegalovirus  
infections: the urgent  
search for  
biomarkers in the  
emerging era of  
universal congenital  
CMV screening  
*Prof Mark R  
Schleiss, University  
of Minnesota  
Medical School,  
USA* \*\*\*

CMV/ HIV  
coinfection in  
perinatally infected  
children in sub-  
Saharan Africa: lung  
disease and immune  
ageing  
*Dr Anthony Hsieh,  
University of Oxford,  
UK*

Respiratory syncytial  
virus  
*Prof Charles Sande,  
KEMRI-Welcome  
Trust, Kenya*

Keynote:  
Vaccinating against  
CMV and its indirect  
effects  
*Prof Stanley A  
Plotkin, University of  
Pennsylvania, USA*

## Session 2: Immuno- compromised Adults

Chair: Prof  
Paul Griffiths, UCL

Discussant:  
Prof Nathan Ford,  
WHO

Human  
cytomegalovirus and  
endothelial  
dysfunction  
*Dr Celestine N  
Wanjalla, Vanderbilt  
University Medical  
Centre, USA* \*\*\*

CMV mismatch and  
health outcomes  
following kidney or  
liver transplant, a  
systematic review  
*Dr Tom Yates,  
University College  
London, UK*

Interactions between  
CMV and respiratory  
viruses  
*Prof Michael  
Boeckh, Fred  
Hutchinson Cancer  
Center, USA*

CMV viraemia as a  
potentially  
modifiable risk factor  
to improve outcomes  
in adults with  
advanced HIV  
disease  
*Dr Jayne Ellis,  
London School of  
Hygiene & Tropical  
Medicine, UK*  
*Dr Caleb Skipper,  
University of  
Minnesota, USA*  
*Prof Joseph N  
Jarvis, London  
School of Hygiene  
and Tropical  
Medicine, UK* \*\*\*

The effect of CMV  
on 'inflammaging'  
*Prof Sara Gianella  
Weibel, University of  
California San  
Diego, USA*

## Session 3: CMV and tuberculosis

Chair: Prof  
Frank Cobelens,  
Amsterdam

Discussant:  
Prof Helen Fletcher,  
J&J

Keynote:  
Cytomegalovirus as  
a viral adjuvant for  
immune function  
across the life  
course  
*Prof Paul Moss  
OBE, University of  
Birmingham, UK*

CMV and incident  
tuberculosis in  
young children  
*Dr Leonardo  
Martinez, Boston  
University School of  
Public Health, USA*

CMV infection in a  
paediatric TB cohort  
*Dr Laura Olbrich,  
LMU Klinikum,  
Germany*

Cytomegalovirus  
infection is a risk  
factor for  
tuberculosis disease  
but not tuberculosis  
infection  
*Dr Lisa Stockdale,  
University of Oxford,  
UK* \*\*\*

Impact of human  
cytomegalovirus  
viremia on the  
progression of TB  
disease among  
people with HIV on  
long-term ART  
*Dr Sivaporn  
Gatechompol,  
Mahidol University,  
Thailand*

Investigating causes  
of mortality in adults  
hospitalised with HIV  
associated  
tuberculosis: the role  
of CMV infection  
*Dr Bianca Sossen,  
University of Cape  
Town, South Africa*

## Session 4: Immuno- competent adults and the elderly

Chair: Prof  
Charlotte Warren-  
Gash, LSHTM

Discussant:  
Prof John Sinclair,  
Cambridge

Can supressing  
CMV replication  
delay tumour  
progression in  
glioblastoma?  
*Prof Cecilia  
Söderberg-Naucler,  
Karolinska Institutet,  
Sweden* \*\*\*

Indirect effects of  
cytomegalovirus in  
depression  
*Dr Jonathan Savitz,  
Laureate Institute for  
Brain Research,  
USA* \*\*\*

Exploring  
interactions between  
human  
cytomegalovirus and  
immunological and  
clinical responses to  
checkpoint  
immunotherapy  
*Prof Benjamin  
Fairfax, University of  
Oxford, UK*\*\*\*

Diminished Anti-  
HCMV T cell  
functionality and  
antibody  
neutralisation  
efficacy in the  
elderly resulting in  
virus replication at  
peripheral sites  
*Dr Mark Wills,  
University of  
Cambridge, UK* \*\*\*

Impact of CMV  
infection on  
heterologous  
vaccine responses  
*Prof Francesco  
Nicolì, University of  
Ferrara, Italy* \*\*\*

The efficacy and  
safety of CMV  
suppression in  
immunocompetent  
patients needing  
intensive care  
*Dr Hannah Imlay,  
University of Utah,  
USA*